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ABSTRACT
Introduction: Onychomycosis is the most
common infectious disease involving nails.
The aim of this study was to evaluate the
antifungal activity of amorolfine 5% nail
lacquer and three different acid-based medical
devices indicated in the treatment of
onychomycosis using an in vitro nail
penetration assay.
Methods: Four products were tested in vitro:
(a) amorolfine 5% nail lacquer; (b) ethyl lactate
and acetic acid; (c) citric acid and urea; (d) ethyl
lactate, glycerin, lactic acid, and citric acid. Test
products were applied to healthy human
cadaver nails and allowed to dry. Disks were
cut from each piece of nail and placed on
seeded agar plates of Trichophyton rubrum.
Following incubation at 30 C, zones of
inhibition were measured.
Results: Amorolfine-treated nails exhibited
inhibitory activity against T. rubrum with a
mean zone of inhibition of 59.2 mm in
diameter. In contrast, all three acid-based
medical devices and the untreated controls
showed no zones of inhibition (mean effective
zones of 0 mm).
Conclusion: In this in vitro nail penetration
model, head-on, comparative study, we showed
that amorolfine 5% nail lacquer possesses
potent antifungal activity, whereas no
antifungal activity was detected for three
commercially available acid-based medical
devices under identical assay conditions.
Funding: Galderma.
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INTRODUCTION
Onychomycosis is a common infectious disease,
which if inappropriately treated can lead to
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spread of the infection, complications,
diminished patient quality of life and may
result in stigmatization [1].
A fungal nail psychosocial perception study
carried out in Hong Kong revealed wide-ranging
misconceptions about onychomycosis
treatments since 26% of respondents thought
disinfectant solutions, such as vinegar or
alcohol, were effective treatments, 42%
incorrectly believed that antibiotics were an
effective treatment, and 14% thought the only
cure was complete removal of the nail [2].
Another survey indicated that many people
with mild, uncomplicated onychomycosis may
never consult a physician [3], and hence are
likely to rely on topical self-medication.
To be effective, a topical treatment for
onychomycosis must have potent fungicidal
activity and be able to penetrate the nail plate,
consisting of dense cross-linked keratin fibers
held together by cysteine-rich proteins and
disulphide bonds [4].
Amorolfine 5% nail lacquer (Loceryl,
Galderma SA, Lausanne, Switzerland) is a
topical antifungal with proven clinical efficacy
in the treatment of onychomycosis caused by
dermatophytes, yeasts and moulds [5–7]. The
active substance, amorolfine hydrochloride
(5.574 g in 100 mL ethanol-based nail lacquer),
has a fungicidal effect and broad antimycotic
spectrum.
A wide range of acid-based medical devices
are commercialized to treat onychomycosis and
common ingredients include acids to inhibit
fungal growth, glycerin to hydrate and
moisturize the nail, and urea to hydrate and
gently dissolve the intercellular matrix of the
nail plate, in addition to penetration enhancers
and film-forming agents. However, there is a
notable lack of published reports on their exact
composition, mechanism of action and whether
they can penetrate through the nail down to
the nail bed.
The objective of this study was to compare
the antifungal activity of amorolfine 5% nail
lacquer with three different commercially
available acid-based medical devices using an
in vitro nail penetration assay.
METHODS
Four products were tested: (a) amorolfine 5%
nail lacquer; (b) ethyl lactate and acetic acid
(Excilor, Vemedia, Diemen, The Netherlands);
(c) citric acid and urea (Scholl Fungal Nail
Treatment, Bayer Healthcare AG, Leverkusen,
Germany); and (d) ethyl lactate, glycerin, lactic
acid, and citric acid (Nailner, YouMedical,
Amsterdam, The Netherlands).
A total of 6 non-diseased big toe nails were
taken from six fresh human cadavers and
washed before use. For each test product, 3
pieces of nail plate from different donors were
treated with 25 lL test product/cm2. The
compound was applied to the center of uncut
nails and allowed to spread evenly. After
air-drying for 24 h, the nail was inverted and
two disks of 4 mm diameter (biopsy punch)
were cut from the center of each piece of nail (a
total of 6 assays per test product). Each disk was
placed, with the treated side facing upwards, at
the center of a seeded agar plate of Trichophyton
rubrum (ATCC MYA-4438TM, Manassas, VA,
USA) (2–5 9 105 conidia/mL). Disks from
untreated nails were used as controls.
Following 4-day incubation at 30 C, the zone
of inhibition was measured with an electronic
caliper. Each test was performed in duplicate.
The mean zone of inhibition ± the standard
error of the mean (SEM) was calculated and
compared between groups. A mean zone of
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inhibition [10 mm was chosen to indicate
potent antifungal activity.
No formal statistical testing was considered
necessary to compare the amorolfine 5% nail
lacquer group with the other treated groups
(whichgavevaluesof zerowithout anyvariability).
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS AND DISCUSSION
The mean nail thickness ranging from 0.86 to
1.09 mm was similar for assays for all test
products (Table 1). Nail disks treated with
amorolfine 5% nail lacquer showed a mean
zone of inhibition ± SEM of 59.2 ± 3.4 mm in
diameter (Table 1 and Fig. 1a). In contrast, the
three acid-based medical devices (Fig. 1b–d) and
the untreated control (Fig. 1e) all showed no
zones of inhibition (mean effective zones of
0 ± 0 mm) (Table 1). Amorolfine 5% nail
lacquer demonstrated potent antifungal
activity when compared to the three medical
devices tested (Fig. 2).
The disk-diffusion method has been widely
used to demonstrate antifungal activity of various
drugs [8, 9]. In this study, amorolfine 5% nail
lacquerdemonstratedeffectiveantifungal activity
(inhibition zone 59.2 mm in diameter),
corroborating previous findings showing that
amorolfine 5% nail lacquer penetrates the nail to
the site of infection in the subungual
compartment [5, 10, 11]. Due to its high
potency, even small amounts of amorolfine
reaching the nail bed inhibit or kill the
pathogens [12] and amorolfine concentrations
deep in the nail bed still exceeded the minimum
inhibitory concentrations of T. rubrum
(\0.001–0.13 lg/mL) [6]. Conversely, the three
acid-based medical products tested did not show
any antifungal activity in the human nail
penetration model used.
This easy-to-use in vitro nail penetration
model was developed taking care to ensure
that the antifungal effects witnessed were from
the test compound penetrating the nail plate
and the test substance could not spread over the
edge of the nail biopsy to influence the growing
fungi beneath the nail plate. The compound
was applied to the center of uncut nails, allowed
to spread evenly and dry before biopsy punches
were taken from the center of the nail specimen
to ensure there was no spillage of the test
compound. By inverting the nail before taking
the biopsy, the disks were cut in the direction of
unexposed nail surface to exposed nail surface
to ensure that the test compound was not
artificially dragged from the biopsy punch. It
is noteworthy that it would also be possible to
increase the biopsy size or seal the margins of
the biopsied nail plate. However, presumably
there was no spreading over the edges since no
zones of inhibition were observed with the
acid-based medical devices under identical assay
conditions in this head-on comparative study.
The role of acidity (low pH) in the
pathogenesis of dermatophytes is complex
[13]. Transmission electron microscopy has
shown that many fungal cells were necrotic
when T. rubrum or Candida albicans was treated
for 60 min in direct contact with 50% K101 nail
solution (Moberg Pharma, Bromma, Sweden), a
topical formulation of pH 4 containing 50 g
propylene glycol, 15 g lactic acid and 10 g urea
[14]. The most prominent changes were
observed with T. rubrum; the cell wall was
clearly damaged, the membrane was disrupted
and the content in the cytoplasm was degraded.
The authors suggested that the presence of a
diol (propylene glycol) disturbed cell wall
integrity by an unspecific mode of action and
the low pHmay have contributed to the efficacy
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[14]. Although pH 4 is not low enough to
inhibit growth, the production of T. rubrum
arthroconidia has been shown to be dependent
on pH with 85% less arthroconidia produced at
pH 4.5 compared to pH 7.5 [15].
A pH of B3 was found to be fungicidal when
Sabouraud dextrose broths of different pH
values were inoculated with T. rubrum and
incubated for 14 days at 25 C [16]. However, a
penetration test in an in vitro porcine nail
model showed that even after 120 applications
of acetic acid (Excilor), the pH measured in the
nails was only 3.37, i.e., not low enough to be
fungicidal [16]. Furthermore, the lowest pH of
3.37 was only measured in the superficial parts
of the nail (0.5 mm depth) [16].
Although acid-based solutions may
penetrate and acidify the nails, as stated by
the manufacturers, the difficulty in obtaining a
low enough pH throughout the nail and in the
nail bed may explain why the three acid-based
medical devices demonstrated no fungicidal
activity in the nail penetration model.
Table 1 Measurement of zones of inhibition












Donor 1 1 0.83 70
Donor 1 2 1.09 51
Donor 2 3 1.08 53
Donor 2 4 1.09 68
Donor 3 5 1.25 52
Donor 3 6 1.25 61




Donor 4 1 0.5 0
Donor 4 2 0.54 0
Donor 2 3 1.02 0
Donor 2 4 0.98 0
Donor 5 5 0.98 0
Donor 5 6 1.11 0
Mean (±SEM) 0.86 0 ± 0
(c) Citric acid
and urea
Donor 1 1 0.69 0
Donor 1 2 0.83 0
Donor 6 3 1.43 0
Donor 6 4 1.46 0
Donor 3 5 1.16 0
Donor 3 6 0.96 0





Donor 4 1 0.5 0
Donor 4 2 0.5 0
Donor 6 3 1.01 0
Donor 6 4 1.01 0
Donor 5 5 1.15 0
Donor 5 6 1.09 0
Mean (±SEM) 0.88 0 ± 0
Table 1 continued











Donor 1 1 1.26 0
Donor 1 2 1.09 0
Donor 2 3 1.33 0
Donor 2 4 0.87 0
Donor 3 5 0.75 0
Donor 3 6 1.02 0
Mean (±SEM) 1.05 0 ± 0
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Possible limitations of this in vitro study are
that nails only received a single application of
test product, and extrapolating from in vitro to
in vivo may not be entirely accurate as in the
nail environment in vivo, natural compounds
may influence fungal growth. However, this
in vitro nail penetration model has been shown
to closely simulate in vivo testing and visually
demonstrates both nail penetration and
antifungal activity after a single application of
amorolfine 5% nail lacquer [11].
Clinical evidence of efficacy of acid-based
solutions against onychomycosis remains scarce
[17, 18]. The K101 nail solution (a mixture of
propylene glycol, lactic acid and urea, pH 4) has
been clinically demonstrated to be effective in
the treatment of distal subungual
onychomycosis [18–20]. In a randomized
placebo-controlled study (n = 346 K101,
n = 147 placebo), more patients with B50%
nail involvement achieved mycological cure
after 26 weeks in the K101 group (27.2%) than
in the placebo group (10.4%; P = 0.0012) [20].
CONCLUSION
This study confirms penetration through the
nail of amorolfine 5% nail lacquer with potent
Fig. 1 Representative plates showing zones of inhibition of
Trichophyton rubrum growth in the nail penetration assay
with a amorolﬁne 5% nail lacquer; b ethyl lactate and acetic
acid; c citric acid and urea; d ethyl lactate, glycerin, lactic
acid, and citric acid; e untreated control
Fig. 2 Effect of amorolﬁne 5% nail lacquer and three medical devices against Trichophyton rubrum in a nail penetration
assay
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antifungal activity in an in vitro human nail
penetration model following a single
application, whereas the three acid-based
products tested had no antifungal activity
under identical assay conditions.
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